elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33425190-CFFF4BDB-A260-463A-BFC6-67230C963D28
Q33425190-CFFF4BDB-A260-463A-BFC6-67230C963D28
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33425190-CFFF4BDB-A260-463A-BFC6-67230C963D28
Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
P2860
Q33425190-CFFF4BDB-A260-463A-BFC6-67230C963D28
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33425190-CFFF4BDB-A260-463A-BFC6-67230C963D28
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
9e3cce1629b584d70f03262230a171a807291b5c
P2860
An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib.